Clinical role of p53 and p21(WAF1/CIP1) in squamous cell carcinoma of the pyriform sinus

Acta Oto-Laryngologica

Volumn 118, Issue 3, 1998, Pages 432-437

  Nibu, Ken Ichi ^a,e   Yanagisawa, Akio ^b   Nakamizo, Munenaga ^c   Hoki, Katsufumi ^d   Nigauri, Tomohiko ^d   Kawabata, Kazuyoshi ^d   Kamata, Shin Etsu ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER INSTITUTE   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Hypopharynx; Lymph node; Prognosis

Indexed keywords

PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SKULL TUMOR; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031777288     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016489850183575     Document Type: Article

References (22)

1. Marks SC, Lolachi CM, Shamsa F, et al. Outcome of pyriform sinus cancer: a retrospective institutional review. Laryngoscope 1996; 106: 27-31.
2. Frank JL, Bur ME, Garb JL, et al. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994; 73: 181-6.
3. Pich A, Chiusa L, Margaria E, Pia F, Navone R. p53 overexpression correlates with proliferative activity and prognosis in carcinomas of the pyriform sinus. Int J Oncol 1995; 6: 1053-8.
4. Laramore GE, Scott CB, Al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on intergroup study 0034. Int J Radiat Oncol Biol Phys 1992; 23: 705-13.
5. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-6.
6. Spruck CH, Tsai UC, Huang DP, et al. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 1992; 52: 4787-90.
7. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinomas. Br J Cancer 1992; 66: 558-62.
8. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992; 84: 1109-14.
9. El-Deiry WS, Tokino T, Valculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
11. Sauter ER, Keller SM, Erner SM. p53 correlates with improved survival in patients with esophageal adenocarcinoma. J Surg Oncol 1995; 58: 269-73.
12. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locolegional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 1580-6.
13. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147: 884-8.
14. WAF1/CIP1 expression of normal and neoplastic tissues. Cancer Res 1995; 55: 2910-9.
15. Cerezo L, Millan I, Torre A, Aragon G, Otero J. Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. Cancer 1992; 69: 224-34.
16. Leemans CR, Tiwari R, Nauta JP, et al. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994; 73: 187-95.
17. Shinohara M, El-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-4.
18. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-74.
19. Ahomadegbe JC, Barrois M, Fogel S, et al. High incidence of p53 alternations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995; 10: 1217-27.
20. Sauter ER, Ridge JA, Gordon J, Eisenberg BL. p53 overexpression correlates with increased survival in patients with squamous cell carcinoma of the tongue base. Am J Surg 1992; 164: 651-3.
21. Muro K, Ohtsu A, Boku N, et al. Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. Jp J Clin Oncol 1996; 26: 65-9.
22. Kastan MB, Onyinye O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.